
Stimulant medications are the first-line pharmacologic therapy for ADHD, but many of these medications are currently in short supply.

Stimulant medications are the first-line pharmacologic therapy for ADHD, but many of these medications are currently in short supply.

On January 6, 2023, the FDA granted lecanemab-irmb (Leqembi) accelerated approval for treating mild cognitive impairment and mild dementia in patients with Alzheimer disease.

After facing challenges, Biogen is discontinuing development and sales of aducanumab (Aduhelm) and focusing on lecanemab (Leqembi).